| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/26/2005 | CA2287333C Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it |
| 04/26/2005 | CA2253871C Ret ligand (retl) for stimulating neural and renal growth |
| 04/26/2005 | CA2155520C Starch hydrolysates as sequesterers |
| 04/21/2005 | WO2005036176A1 Cell surface molecules as markers and therapeutic agents against kidney cancers |
| 04/21/2005 | WO2005035727A2 Polymer derivatives |
| 04/21/2005 | WO2005035651A1 Finely particulate composite containing carbon compound encapsulated therein |
| 04/21/2005 | WO2005035574A1 IgM HIGH CONCENTRATION STABILIZED SOLUTION |
| 04/21/2005 | WO2005035572A2 Antibody compositions and methods |
| 04/21/2005 | WO2005035567A1 Chimeric mhc protein and oligomer thereof for specific targeting |
| 04/21/2005 | WO2005035565A1 Il-21 derivatives |
| 04/21/2005 | WO2005035546A1 Peptide nucleic acid conjugates and uses thereof |
| 04/21/2005 | WO2005035441A2 Subtituted fullerene compositions and their use as antioxydants |
| 04/21/2005 | WO2005035003A2 Compositions and methods for increasing drug efficiency |
| 04/21/2005 | WO2005035002A1 Fibrinogen targetting microparticles for promoting haemostasie |
| 04/21/2005 | WO2005035001A1 Sustained release l-arginine formulations and methods of manufacture and use |
| 04/21/2005 | WO2005034999A2 Composition comprising association complex of a pharmaceutical and a poloxamer |
| 04/21/2005 | WO2005034997A2 Conjugate of a photosensitiser and a bacteriophage |
| 04/21/2005 | WO2005034969A1 Medicament on the basis of honey, preparation and use thereof |
| 04/21/2005 | WO2005034968A1 Solution for cessation of smoking and method to use |
| 04/21/2005 | WO2005034945A1 Use of norphenazone and coenzyme q for curing arthrose, arthritis and osteoarthritis |
| 04/21/2005 | WO2005034930A1 Pellets containing venlafaxine hydrochloride |
| 04/21/2005 | WO2005034925A1 Lowly irritative adhesive patch |
| 04/21/2005 | WO2005034913A1 Novel liquid preparation composition |
| 04/21/2005 | WO2005034909A2 Hyperbranched polymer conjugates via non-enzymatic cleavable linker |
| 04/21/2005 | WO2005034907A1 Skin care topical ointment |
| 04/21/2005 | WO2005034877A2 G-csf transferrin fusion proteins |
| 04/21/2005 | WO2005023310A3 Polyamine-metal chelator conjugates |
| 04/21/2005 | WO2005020965A3 Skeletally targeted nanoparticles |
| 04/21/2005 | WO2005020956A3 Microparticles |
| 04/21/2005 | WO2005016365A3 Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| 04/21/2005 | WO2005011737A3 Pharmaceutical combinations and formulations with improved stability |
| 04/21/2005 | WO2005004878A3 Multi-use vessels for vitamin d formulations, preferably administeredat high dose and periodically |
| 04/21/2005 | WO2005004842A3 Formulations for coated microprojections containing non-volatile counterions |
| 04/21/2005 | WO2005003296A3 Albumin fusion proteins |
| 04/21/2005 | WO2005002625A3 In-situ gelling drug delivery system |
| 04/21/2005 | WO2005002544A3 Stabilized particle dispersions containing nanoparticles |
| 04/21/2005 | WO2004100866A3 Alcohol-free transdermal analgesic composition |
| 04/21/2005 | WO2004096285A3 Anti-infective phosphonate conjugates |
| 04/21/2005 | WO2004091530B1 Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom |
| 04/21/2005 | WO2004071386A3 Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use |
| 04/21/2005 | WO2004060268A8 A method and article to control cellulite |
| 04/21/2005 | WO2004041194A3 Inhibition of hiv-1 replication |
| 04/21/2005 | WO2004018066A3 Aqueous two-phase systems for particle manipulation and encapsulation within microscopic volumes |
| 04/21/2005 | WO2004005313A3 Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 04/21/2005 | WO2003105753A3 Targeted enzymes and methods of making and using targeted enzymes. |
| 04/21/2005 | WO2003101421A8 Film-shaped preparations with improved chemical stability containing active substances and method for the production thereof |
| 04/21/2005 | WO2003061584A3 Novel substituted benzimidazole dosage forms and method of using same |
| 04/21/2005 | WO2003061559A3 Binding peptides specific for the extracellular domain of erbb2 and uses therefor |
| 04/21/2005 | WO2002098348A3 Glp-1 formulations with protracted time action |
| 04/21/2005 | US20050085860 Transdermal/transmucosal preparations for electroporation |
| 04/21/2005 | US20050085758 Dilute aqueous solution containing epidermal growth factor in gel |
| 04/21/2005 | US20050085619 water-soluble compound that includes a polyether or vinyl ether with at least one terminal azide moiety; for linkage of water soluble polymers to a therapeutic agent |
| 04/21/2005 | US20050085542 Solution for peritomeal dialysis |
| 04/21/2005 | US20050085485 Parkinson's disease; mixing with lactose and starches |
| 04/21/2005 | US20050085462 Solid oral formulation coated with hydroxypropyl methylcellulose; the polymer coating is free of polyethylene glycol |
| 04/21/2005 | US20050085448 Viricides against herpes virus; autoimmune disease; antitumor agents |
| 04/21/2005 | US20050085446 bactericial composition for topical application to the eye containing a soluble polymer to reduce the precipitation of the bactericide on the cornea; particularly a fluoroquinolone, a steroidal or non-steroidal anti-inflammatory agent, cyclodextrin, a hydroxy acid and water with a pH between 4.5 and 7. |
| 04/21/2005 | US20050085445 Mixture containing hydrophilic additive; measured dosage aerosol inhaler |
| 04/21/2005 | US20050085440 Formulation |
| 04/21/2005 | US20050085437 Crystalline drug form |
| 04/21/2005 | US20050085434 Ballast administering to human skins; dna vaccine; high density core overcoated with amorphous reservoir containing dna |
| 04/21/2005 | US20050085432 Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections |
| 04/21/2005 | US20050085426 Acid-sensitive compounds, preparation and use thereof |
| 04/21/2005 | US20050085415 Nanoparticles injected directly into eye; integrin receptor antagonist; angiogenesis inhibitor, polypeptide |
| 04/21/2005 | US20050085413 Dimeric pharmaceutical compounds and their use |
| 04/21/2005 | US20050084958 Propagating animal muscle tissue in vitro for use in engineered meat product for human consumption; food processing |
| 04/21/2005 | US20050084906 Preferably chimerized or humanized antibodies; are active in vivo on all the types of tumors expressing IGF-IR including estrogen-dependent tumors of the breast and tumors of the prostate; they interact little or not at all with the IR receptor on insulin. |
| 04/21/2005 | US20050084553 Composition containing moutan root bark extract as active ingredient |
| 04/21/2005 | US20050084549 Fiber rich fraction of Trigonella Foenum-graceum seeds and its use as a pharmaceutical excipient |
| 04/21/2005 | US20050084538 Ultrasonic concentration of drug delivery capsules |
| 04/21/2005 | US20050084537 Sustained-release compositions |
| 04/21/2005 | US20050084534 Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
| 04/21/2005 | US20050084533 Polymer composite with internally distributed deposition matter |
| 04/21/2005 | US20050084516 Process for making gel films |
| 04/21/2005 | US20050084513 Nanocoating for improving biocompatibility of medical implants |
| 04/21/2005 | US20050084506 Amide compounds such as (R)-methyl 2-(3-chloro-4-methoxybenzamido)-4-methylpentanoate and urea compounds such as 1-(2-chlorophenyl)-3-(heptan-4-yl)urea for modulating taste of food or drug products |
| 04/21/2005 | US20050084489 Synergistic administration of Vitaxin, a FAB fragment, or a competitive binding antibody for binding integrin alpha V beta 3 with the enzyme inhibitor; antiinflammatory, anticarcinogenic agents; autoimmune and metabolic bone disorders |
| 04/21/2005 | US20050084486 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 04/21/2005 | US20050084482 As an antiinflammatory agent for gastrointestinal inflammation involved with inflammatory bowel disease or irritable bowel syndrome |
| 04/21/2005 | US20050084479 Especially lactic acid bacteria as drug delivery devices in combination with edible carriers; tissue targeted therapy |
| 04/21/2005 | US20050084470 Anionic surfactants, seed oil microparticles and a moisturizer; moisturization with concurrent exfoliation |
| 04/21/2005 | US20050084458 Solution or dispersion of lipophilic dialkyl diselenide such as dihexyl diselenide in a carrier for topical use |
| 04/21/2005 | US20050084456 Functionalized particles |
| 04/21/2005 | US20050084453 Mixing a sterol or a polyether modified phospholipid capable of forming a liposome with a supercritical carbon dioxide, contacting water-soluble nonionic iodine compound with phospholipid to form a liposome containing vesicles including the iodine compound; chlorine-free solvent |
| 04/21/2005 | CA2578473A1 Peptide nucleic acid conjugates and uses thereof |
| 04/21/2005 | CA2542474A1 Medicament on the basis of honey, preparation and use thereof |
| 04/21/2005 | CA2542179A1 Il-21 derivatives |
| 04/21/2005 | CA2541317A1 Multi-layered polymerizing hydrogels for tissue regeneration |
| 04/21/2005 | CA2540307A1 Subtituted fullerene compositions and their use as antioxydants |
| 04/21/2005 | CA2540202A1 Sustained release l-arginine formulations and methods of manufacture and use |
| 04/21/2005 | CA2539999A1 Antibody compositions and methods |
| 04/21/2005 | CA2537315A1 Protein biomaterials and biocoacervates and methods of making and using thereof |
| 04/20/2005 | EP1524029A1 Self-Emulsifying Compositions |
| 04/20/2005 | EP1523994A1 Medicinal composition for regulating release and process for producing the same |
| 04/20/2005 | EP1523993A1 Polypeptide compositions with improved stability |
| 04/20/2005 | EP1523984A1 Pharmaceutical composition comprising oxoplatin, salts and derivatives thereof |
| 04/20/2005 | EP1523983A1 Pharmaceutical composition comprising fenofibrate and process for its preparation |
| 04/20/2005 | EP1523976A2 Pharmaceutical formulations of salmeterol |
| 04/20/2005 | EP1523975A2 Pressurised metered dose inhalers (MDI) |
| 04/20/2005 | EP1523974A1 Composition for rapid disintegrating tablet in oral cavity |